5-fluorouracil. Using a Japanese Adverse Drug Event Report database, Oshima et al reported that 49 of 16 441 patients (0.3%) treated with systemic vascular endothelial growth factor pathway inhibitors (VPIs) developed aortic dissection (30 times higher than in subjects not exposed to VPIs). This includes 11 of 4975 (0.22%) patients treated with sorafenib. 2 While aortic dissection is rare, it is likely caused by an increase in blood pressure and delayed healing of damaged endothelium. Patients on VPI therapy should be monitored closely for elevation in blood pressure and aortic dissection.
